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ABSTRACT 
 
Background: It is now well-demonstrated that histone demethylases play an important role in developmental 
controls, cell-fate decisions, and a variety of diseases such as cancer. Lysine-specific demethylase 5D (KDM5D) is a 
male-specific histone demethylase that specifically demethylates di- and tri-methyl H3K4 at the start site of active 
gene. In this light, the aim of this study was to investigate isoform/transcript-specific expression profiles of 
KDM5D in three prostate cancer cell lines, Du-145, LNCaP, and PC3. Methods: Real-time PCR analysis was 
performed to determine the expression levels of different KDM5D transcripts in the prostate cell lines. A gene 
regulatory network was established to analyze the gene expression profile. Results: Significantly different 
expression levels of both isoforms were found among the three cell lines. Interestingly, isoform I was expressed in 
three cell lines while isoform III did only in DU-145. The expression levels of both isoforms were higher in DU-145 
when compared to other cell lines (P<0.0001). The observed expression profile was determined by using 
regulatory network analyses. Conclusion: The present study, for the first time, not only showed the expression 
profiles of KDM5D isoforms in prostate cancer cell lines but also evaluated the effects of the gene regulatory 
network on the expression profile of this gene. DOI: 10.7508/ibj.2016.02.007 
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INTRODUCTION 
 
ysine-specific demethylase 5D (KDM5D), so-
called JARID1D, SMCY, and H-Y antigen, is a 
histone demethylase located on the Y 
chromosome in humans and most mammals
[1]
.  Histone 
methylation and demethylation have been 
demonstrated to play an important role in gene 
regulation and biological events during the develop-
ment of diseases, including neurological disorders and 
a variety of cancer types
[2]
. The emergence of histone 
lysine demethylases, as therapeutic targets, provides an 
opportunity to ensure the continuing fight against 
cancer
[3]
. 
Similar to other KDM5 family members, KDM5D is 
able to demethylate di- and tri-methyl H3K4, 
suggesting that it may repress the expression of certain 
genes at the transcription level
[4]
. A deletion analysis of 
Y chromosome-specific genes in human prostate 
cancer revealed that the KDM5D gene is deleted in 
52% of cases
[5]
, demonstrating its involvement in 
cancer pathogenesis. Prostate cancer, as the sixth 
leading cause of death in the world, can spread to 
certain areas of the body, including bones and lymph 
nodes
[6]
. 
Amino  acid sequencing has revealed that KDM5D  
is homologous to KDM5C (XE169, JARID1C, SMCX) 
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Fig. 1. Three splice variants of KDM5D based on Ensembl database search. All isoforms have a common transcriptional start site 
but different numbers of exons. The difference in the number of exons has been marked with dashed box. The site of primers are 
shown in the Figure. Dashed lines (             ) indicate the exon site. Sequences of primers are highlighted with arrow. Slashed (///) lines 
show the intron position.  
 
 
with 86% identity and 91% similarity
[7]
. On the one 
hand, the same evolutionary origin implicates a 
functional equivalence of SMCY/SMCX
[1,8]
. 
Figure 1 shows multiple transcript variants encoding 
three different isoforms. KDM5D isoform transcripts 
are found to be predominantly expressed in all male 
tissues. Most tissues, except spleen, exhibit differential 
expression of KDM5D transcript variants
[7]
. 
Alternative splicing of mRNA precursors allows many 
gene products with different functions to be produced 
from a single-coding sequence. In fact, this is  
one of the most significant aspects by which the 
genome acquires the ability to prime complex 
functional responses to different growth factors and 
environmental stimuli
[9]
. Several different mechanisms 
can contribute to changes in the regulation of transcript 
expression. Altered expression profiles or point 
mutations in components of the splicing machinery 
lead to different splicing patterns. An alteration in 
alternative splicing programs can be attributed to 
different diseases such as cancer
[9,10]
. 
The principal aim of this study was to investigate the 
KDM5D isoform-specific expression pattern in three 
human prostate cancer cell lines (DU-145, PC3, and 
LNCaP) with different behaviors in tumourgenicity 
and other properties (Table 1). Furthermore, a gene 
regulatory network was established to evaluate the 
expression changes of factors corresponding to 
KDM5D, based on the microarray data and 
transcription factor profiles.  
 
 
MATERIALS AND METHODS 
 
Prostate cancer cell lines, Du-145, LNCaP, and PC3, 
obtained from the National Cell Bank of Iran (Pasteur 
Institute of Iran, Tehran), and cultured in RPMI 1640 
medium (Gibco RL, Grand Island, NY) supplemented 
with 10% fetal bovine serum, 100 U/ml penicillin, 1% 
glutamine, and 1% non-essential amino acids in a  
humidified atmosphere containing 5% CO2. All of the 
cells were seeded at 60% to 80% confluency. 
 
RNA extraction and real-time PCR analysis 
Total RNA was extracted using Trizol reagent 
(Invitrogen, Carlsbad, CA, USA). The integrity and 
quality of RNA samples were assessed by a Nanodrop 
(ND-1000) spectrophotometer. Reverse transcription 
was carried out using M-MuLV reverse transcriptase 
(Fermentas Inc., MD, USA) from 1 µg of total RNA, 
according to the manufacturer’s protocol. Quantitative 
real-time PCR was performed to determine the 
expression of the KDM5D isoform with the SYBR 
Green PCR master mix (Applied Biosystems, Foster 
City, CA, USA) using an Applied Biosystems 7900 
instrument. Relative mRNA levels were calculated 
using the comparative CT method as described by the 
manufacturer (Applied Biosystems, Foster City, CA, 
USA) with beta-actin as an internal control for 
normalization. Primer sequences used for quantitative 
real-time PCR are listed in Table 2. 
 
 
Table 1. Some properties of prostate cancer lines used in 
this study 
 
Cell line Tumorgenicity 
Y 
chromosome 
Androgen 
sensitivity 
PC3 High delete insensitive 
DU-145 moderate intact insensitive 
LNCaP low intact sensitive 
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  Table 2. Primer sequences  
 
 
 
The primers were designed by Primer 3 (v. 2.2.3) and checked by NCBI primer BLAST 
 
 
Construction of gene regulatory network 
The Transfac data related to KDM5D was primarily 
extracted and then merged with protein-protein 
interaction (PPI) networks from PPI databases using 
Cytoscape software (ver. 3.1.1). The data extracted 
directly from the GEO records, GSE33455 and 
GSE32474, were transformed to the network nodes. 
The network edges were created according to the 
combined scores obtained from PPI data.  
 
Statistical analysis 
All experiments were performed in triplicates, and 
the results were expressed as mean ± standard 
deviation (SD). Statistical analyses were performed 
using one-way ANOVA, followed by Tukey’s post-
test. P<0.05 was considered to be statistically 
significant. 
 
 
RESULTS 
 
Expression of KDM5D isoforms in prostate cancer 
cell lines 
Real-time RT-PCR analysis was performed to 
determine the expression levels of different KDM5D 
transcripts in prostate cell lines, LNCaP, DU-145, and 
PC3 cells. Interestingly, the same expression pattern 
was found in both isoforms studied. As shown in 
Figure 2, the expression levels of these two isoforms in 
DU-145 cell line were found to be higher than the other 
cell lines (P<0.0001). KDM5D isoform I showed a 
minimum expression value in the prostate cancer cell 
lines PC3 and LNCaP, as illustrated in Fig. 2a. 
Furthermore, the expression level of isoform I in 
LNCaP was more than the cancer cell line PC3 
(P<0.006). More importantly, KDM5D isoform III was 
expressed only in DU-145 but not in PC3 and LNCaP, 
as depicted in Fig. 2b. 
 
Network analysis 
To explain different expression patterns among 
different cell lines, we established a gene regulatory 
network corresponding to KDM5D gene expression in 
the cell lines. As shown in Figure 3, the networks share 
the same topology so that the size of nodes involved 
directly in KDM5D (including PCGF6, ZFX, RPS4X, 
USP9X, and E2F6) is not different between the cell 
lines. In addition, no significant dynamic difference 
was found between the networks. The edges between 
nodes representing individual molecular reactions were 
the same between the networks. 
 
 
 
 
Fig. 2. Relative expression of a) KDM5D isoform 1 and b) KDM5D isoform 3. Experiments were carried out in triplicate, and data 
were presented as mean ± SD. Both of isoforms are expressed in DU-145 higher than the other cell lines (P<000.1). The expression 
level of isoform1 in LNCAP is more than PC3 cell line (P<00.6). 
Gene Ref Sequence no. Forward primer (5' to3') Reveres primer (5' to3') 
KDM5D-isoform1 NM_001146705 ACAAAGTCTCACTGTGTTGA ATACTCCTGTAATCCCAACAC 
KDM5D-Isoform3 NM_001146706 AAGGCTAAATGAACTGGAG GTGTTACATTGCTTACTAAGG 
B-Actin NM_001101 TCCCTGGAGAAGAGCTACG GTAGTTTCGTGGATGCCACA  
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Fig. 3. Gene regulatory network in a) PC3 and b) DU-145 cell lines. Green nodes and edges represent the lowest expression, red 
nodes and edges show the highest expression and the other colors indicate expression values between maximum and minimum. Size of 
nodes also indicate the level of gene expressions. Thickness of edges indicates the combined scores. 
 
 
DISCUSSION 
 
In the present study, the specific primers for 
quantitative RT-PCR were developed to detect 
KDM5D isoforms-I and -III, and to investigate their 
expression pattern in the prostate cancer cell lines. 
Isoforms I and III encode proteins with a predicted 
molecular mass of 174 and 177 kDa, respectively, as a 
result of which Western-blot could not discriminate 
between the two isoforms. 
It is well-known that isoform-level expression 
profiles provide better discrimination between cancer 
and non-cancer cells, as compared to the gene-level 
expression profiles. This is because of the fact that 
mammalian genes utilize different promoter elements 
and alternative splicing processes in various tissues, 
developmental stages, and cell lines
[11]
. However, the 
findings from the present study demonstrated that there 
is a significant difference in the expression level of 
both isoforms among different prostate cancer cell 
lines with different properties (Table 1). In addition, 
there is strong evidence that protein networks, 
including regulatory proteins, have the ability to 
determine the expression profile. To explain the 
different expression patterns between androgen-
insensitive prostate cancer cell lines Du-145 and PC3, 
a KDM5D gene regulatory network was established 
based on the PPI data merged with Transfac data. 
Interestingly, no significant difference was found in 
network topology and dynamic output between the two 
cell lines. A network topology deﬁnes the connection 
between nodes while a dynamic gene network 
describes the change of gene expression at a given 
time
[12]
. 
Lau and Zhang
[13]
 reported the expression of 
KDM5D and some Y chromosome genes in the cell 
line PC3. However, cytogenetic evidence demonstrated 
the lack of Y chromosome detection in the cell line. 
Therefore, they concluded that the aberrant expression 
of KDM5D and other Y chromosome genes in the cell 
line PC3 indicate that a part of the chromosome is in 
fact more likely to have been retained (or translocated 
to other chromosomes) in its genome. Nevertheless, we 
still cannot rule out the possibility that the RT-PCR 
products might be derived from the transcripts of the 
respective X alleles or homologues.  
A comparison between nodes and edges in the 
regulatory network in PC3 and DU-145 (Fig. 3) 
showed that there is no significant difference between 
regulatory networks governing the expression pattern 
of KDM5D in the prostate cancer cell lines studied. 
The results from this study demonstrated that the 
difference in the expression between cell lines is not 
related to that found in a regulatory factor. However, 
the aberrant expression of KDM5D derived from 
transcripts of the respective X alleles or homologues 
may be able to explain the difference in expression 
patterns of the cell lines. 
The same expression pattern of two isoforms was 
found in Du-145 while the expression level of isoform 
(a) (b) 
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I was demonstrated to be higher than that of isoform III 
in other cell lines. Both mutations in splicing proteins 
and point mutations in splice acceptor sites or donor 
sites led to different splicing patterns in a variety of 
transcripts
[10]
.  
Unlike the two other cell lines, LNCaP cells are 
androgen-sensitive human prostate adenocarcinoma 
cells
[14]
. The androgen receptor signaling axis plays a 
critical role in development, function, and homeostasis 
of the prostate
[15]
. The results from this study revealed 
that there is no correlation between the expression 
levels of the isoforms and androgen sensitivity or 
insensitivity. Although the three cell lines were 
considered to be different tumorgenicity, the present 
study demonstrated that there is no correlation between 
the isoform expression level and the level of 
tumorgenicity. 
In conclusion, our results, for the first time, showed 
the isoform/transcript-specific expression of KDM5D 
in the prostate cancer cell lines. In addition, 
bioinformatics analyses identified the effect of gene 
regulatory network on the KDM5D expression profile 
in different cell lines. 
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